Should Low Molecular Weight PSMA Targeted Ligands Get Bigger and Use Albumin Ligands for PSMA Targeting?

Prostate Specific Membrane Antigen (PSMA) is strongly expressed in prostate cancer. Recently a number of low-molecular-weight inhibitors have demonstrated excellent PSMA targeting activity for both imaging as well as Lutecium-177 radiotherapy in human trials. The paper by Choy et al raises the quest...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Steve S., Heston, Warren D.W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2017
Materias:
Editorial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5479280/
https://www.ncbi.nlm.nih.gov/pubmed/28638479
http://dx.doi.org/10.7150/thno.20284
_version_ 1783245109541732352
author Huang, Steve S.
Heston, Warren D.W.
author_facet Huang, Steve S.
Heston, Warren D.W.
author_sort Huang, Steve S.
collection PubMed
description Prostate Specific Membrane Antigen (PSMA) is strongly expressed in prostate cancer. Recently a number of low-molecular-weight inhibitors have demonstrated excellent PSMA targeting activity for both imaging as well as Lutecium-177 radiotherapy in human trials. The paper by Choy et al raises the question of whether we can further increase the effectiveness of PSMA targeted therapy by adding an albumin-binding entity to low-molecular-weight agents
format Online
Article
Text
id pubmed-5479280
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Ivyspring International Publisher
record_format MEDLINE/PubMed
spelling pubmed-54792802017-06-21 Should Low Molecular Weight PSMA Targeted Ligands Get Bigger and Use Albumin Ligands for PSMA Targeting? Huang, Steve S. Heston, Warren D.W. Theranostics Editorial Prostate Specific Membrane Antigen (PSMA) is strongly expressed in prostate cancer. Recently a number of low-molecular-weight inhibitors have demonstrated excellent PSMA targeting activity for both imaging as well as Lutecium-177 radiotherapy in human trials. The paper by Choy et al raises the question of whether we can further increase the effectiveness of PSMA targeted therapy by adding an albumin-binding entity to low-molecular-weight agents Ivyspring International Publisher 2017-04-01 /pmc/articles/PMC5479280/ /pubmed/28638479 http://dx.doi.org/10.7150/thno.20284 Text en © Ivyspring International Publisher This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) license (https://creativecommons.org/licenses/by-nc/4.0/). See http://ivyspring.com/terms for full terms and conditions.
spellingShingle Editorial
Huang, Steve S.
Heston, Warren D.W.
Should Low Molecular Weight PSMA Targeted Ligands Get Bigger and Use Albumin Ligands for PSMA Targeting?
title Should Low Molecular Weight PSMA Targeted Ligands Get Bigger and Use Albumin Ligands for PSMA Targeting?
title_full Should Low Molecular Weight PSMA Targeted Ligands Get Bigger and Use Albumin Ligands for PSMA Targeting?
title_fullStr Should Low Molecular Weight PSMA Targeted Ligands Get Bigger and Use Albumin Ligands for PSMA Targeting?
title_full_unstemmed Should Low Molecular Weight PSMA Targeted Ligands Get Bigger and Use Albumin Ligands for PSMA Targeting?
title_short Should Low Molecular Weight PSMA Targeted Ligands Get Bigger and Use Albumin Ligands for PSMA Targeting?
title_sort should low molecular weight psma targeted ligands get bigger and use albumin ligands for psma targeting?
topic Editorial
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5479280/
https://www.ncbi.nlm.nih.gov/pubmed/28638479
http://dx.doi.org/10.7150/thno.20284
work_keys_str_mv AT huangsteves shouldlowmolecularweightpsmatargetedligandsgetbiggerandusealbuminligandsforpsmatargeting
AT hestonwarrendw shouldlowmolecularweightpsmatargetedligandsgetbiggerandusealbuminligandsforpsmatargeting

Ejemplares similares